Stock ALDX ALDEYRA THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Aldeyra Therapeutics, Inc.

Equities

ALDX

US01438T1060

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-18 pm EDT 		5-day change 1st Jan Change
3.98 USD +0.25% Intraday chart for Aldeyra Therapeutics, Inc. -9.55% +13.39%
Apr. 04 North American Morning Briefing : Focus Turns to -2- DJ
Apr. 03 Oppenheimer Upgrades Aldeyra Therapeutics to Outperform From Perform, $10 Price Target MT

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration

Latest news about Aldeyra Therapeutics, Inc.

North American Morning Briefing : Focus Turns to -2- DJ
Oppenheimer Upgrades Aldeyra Therapeutics to Outperform From Perform, $10 Price Target MT
Transcript : Aldeyra Therapeutics, Inc. - Special Call
Aldeyra Therapeutics, Inc. Announces Clinical Development Plan for Resubmission of New Drug Application for Reproxalap in Dry Eye Disease CI
Aldeyra Therapeutics Insider Sold Shares Worth $580,760, According to a Recent SEC Filing MT
Aldeyra Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Aldeyra Therapeutics Provides Clinical and Regulatory Update and Announces Advancement of Rasp Platform in Systemic and Retinal Inflammatory Diseases CI
Aldeyra Therapeutics, Inc. and Abbvie to Enter into the Co-Development, Co-Commercialization and License Agreement CI
Aldeyra Therapeutics Shares Jump as Skin Drug Shows Significant Improvement in Clinical Trial MT
Transcript : Aldeyra Therapeutics, Inc. - Special Call
Aldeyra Therapeutics' skin disease drug succeeds in mid-stage study RE
Aldeyra Therapeutics' eczema drug succeeds in mid-stage study RE
Aldeyra Therapeutics, Inc. Announces Positive Top-Line Results from A Phase 2 Clinical Trial of ADX-629 in Patients with Atopic Dermatitis CI
Aldeyra Therapeutics, Inc.(NasdaqCM:ALDX) dropped from S&P Biotechnology Select Industry Index CI
Transcript : Aldeyra Therapeutics, Inc. - Special Call
Aldeyra NDA for Reproxalap Did Not Demonstrate Efficacy for Dry Eye Treatment MT
Aldeyra Therapeutics Says Additional Trial Needed For FDA Approval of Dry-Eye Disease Treatment DJ
Aldeyra Therapeutics Halted After-Hours - FDA Says NDA Did Not Demonstrate 'Efficacy in Treating Ocular Symptoms Associated With Dry Eyes'; Additional Study Recommended MT
Aldeyra Therapeutics, Inc. Receives Complete Response Letter from the U.S. Food and Drug Administration for the Reproxalap New Drug Application for the Treatment of Dry Eye Disease CI
Aldeyra Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Health Care Up Amid Mixed Earnings -- Health Care Roundup DJ
Sector Update: Health Care Stocks Rise in Late Afternoon Trading MT
Sector Update: Health Care MT
Aldeyra Shares Continue to Rally After AbbVie Agrees to Licensing Option DJ
Top Midday Gainers MT

Chart Aldeyra Therapeutics, Inc.

Chart Aldeyra Therapeutics, Inc.
More charts

Company Profile

Aldeyra Therapeutics, Inc. is a biotechnology company, which is engaged in discovering therapies designed to treat immune-mediated diseases. The Company's product candidates include reactive aldehyde species (RASP) modulators ADX-629, ADX-246, ADX-248, and chemically related molecules for the treatment of systemic and retinal immune-mediated diseases. Its pre-commercial product candidates are reproxalap, a RASP modulator for the potential treatment of dry eye disease and allergic conjunctivitis, and ADX-2191, a novel formulation of intravitreal methotrexate for the treatment of proliferative vitreoretinopathy and retinitis pigmentosa. Its ADX-629, is an orally administered RASP modulator in clinical development for atopic dermatitis, idiopathic nephrotic syndrome, moderate alcohol-associated hepatitis, chronic cough, and Sjogren-Larsson Syndrome. Its preclinical RASP platform includes ADX-246 and ADX-248 in development for metabolic, retinal diseases and systemic inflammatory diseases.
Sector
Biotechnology & Medical Research
Calendar
2024-05-01 - Q1 2024 Earnings Release (Projected)
Related indices
Russell 2000
More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
3.97 USD
Average target price
9.571 USD
Spread / Average Target
+141.09%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
ALDEYRA THERAPEUTICS, INC. Stock Aldeyra Therapeutics, Inc.
+13.39% 234M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-3.30% 102B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+1.79% 96.84B
ARGENX SE Stock argenx SE
-0.44% 21.48B
BIONTECH SE Stock BioNTech SE
-18.35% 20.82B
GENMAB A/S Stock Genmab A/S
-7.45% 18.6B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-40.31% 16.81B
BEIGENE, LTD. Stock BeiGene, Ltd.
-26.84% 13.78B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+0.59% 13.4B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+20.86% 11.06B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. ALDX Stock
  4. News Aldeyra Therapeutics, Inc.
  5. Aldeyra Therapeutics Completes Enrollment in Dry Eye Disease Phase 3 Trial